We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lung Collectins Both Enhance and Suppress Immune Response

By Biotechdaily staff writers
Posted on 14 Oct 2003
Researchers have shown that the two lung collectins, surfactant proteins A and D (SP-A and SP-D), act in a dual manner to enhance or suppress inflammatory mediator production depending on binding orientation.

Collectin (collagen-like lectin) is a subgroup of C-type (i.e., calcium-dependent) animal lectins characterized by the presence of collagen-like sequences (Gly-Xaa-Yaa triplet). More...
The collectins include three serum proteins, mannan-binding protein (MBP), bovine conglutinin and bovine collectin-43 (CL-43), and two lung surfactant proteins (SP-A and SP-D). The collectins bind to terminal nonreducing sugar residues, mannose, GlcNAc, fucose, and glucose. SP-D binds to maltose. They play important roles in innate immunity without involvement of antibodies.

Surfactant proteins A and D are composed of two regions; a globular head domain that binds pathogen-associated molecular patterns (PAMPs, conserved cell-surface structures that are unique to bacteria and are recognized by the innate sector of the immune system) and a collagenous tail domain that initiates phagocytosis.

Investigators at National Jewish Medical and Research Center (Denver, CO, USA; www.njc.org) working with mice found that SP-A and SP-D bind PAMPs through their globular heads to initiate a signaling pathway that blocks proinflammatory mediator production. In contrast, their collagenous tails stimulate proinflammatory mediator production through binding to calreticulin/CD91. These findings were published in the October 3, 2003, issue of Cell.

"The lung collectins can effectively discriminate between conditions in the lung that warrant an immune response and those that do not,” explained senior author Dr. Peter Henson, professor of pediatrics at National Jewish Medical and Research Center. "They do this with a clever mechanism, inhibiting the immune response with one end of their structure and promoting it with the other. These findings should help clarify confusion about the lung collectins. Lung collectins play not one role, but two as they protect the lung not only from harmful pathogens, but also from harmful overreaction by the immune system.”



Related Links:
National Jewish Medical and Research Center

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.